Please provide your email address to receive an email when new articles are posted on . Lung clearance index improved in month 3 and 12 of elexacaftor/tezacaftor ...

Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adolescents aged 12 years and older receiving cystic ...

This Cystic Fibrosis Awareness Month, Children's Hospital Colorado (Children's Colorado) is highlighting a growing shift in ...

Cystic fibrosis is a genetic disease that causes serious and sometimes fatal respiratory and digestive disorders. A new treatment, available since 2020, improves lung function and quality of life.

Our findings show that many have stepped back from some of those time-consuming therapies thanks to ETI." Scott Sagel, MD, PhD, lead author, professor of pediatrics-pulmonary medicine at the CU ...

SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...

Hundreds of people with the most common type of cystic fibrosis could be offered a new triple therapy after the National Institute for Health and Care Excellence (NICE) recommended ...

KB407’s positive set of results presented at ATS 2026 follows a set of similar positive results that were announced for the ...

Researchers conducted a phase 3b open-label trial at multiple sites in Australia and the European Union to assess the effect of elexacaftor-tezacaftor-ivacaftor, an approved medication for cystic ...

Repeated exposure to general anesthesia did not negatively affect neurobehavioral outcomes among children with cystic fibrosis, the randomized phase IV CF-GAIN trial showed. The mean composite score ...